Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects

Journal of Clinical Pharmacology
Zhenhua XuHonghui Zhou

Abstract

This study characterized the pharmacokinetics (PK) of golimumab, an antitumor necrosis factor alpha human IgG1kappa monoclonal antibody, after a single intravenous (IV) or subcutaneous (SC) administration in healthy subjects and determined the absolute bioavailability of SC golimumab delivered at 3 different anatomical regions. Seventy-eight healthy adult males were randomly assigned to receive a single dose of golimumab 100 mg by IV (30-minute infusion, n = 23) or SC administration at different sites (upper arm, n = 18; abdomen, n = 18; thigh, n = 19). Serial blood samples were collected for PK characterization. Following IV administration, the mean maximum observed serum golimumab concentration (C(max)) and the mean area under the concentration versus time curves from time zero to infinity (AUC(0-infinity)) were 29.5 +/- 5.8 microg/mL and 195.9 +/- 48.9 microg x d/mL, respectively. After SC administration, the mean values of C(max) and AUC(0-infinity) were 6.3 +/- 2.8 microg/mL and 100.1 +/- 29.2 microg x d/mL, respectively. The median terminal half-life was similar for SC and IV administration (10.9 and 11.8 days, respectively). The overall mean bioavailability of SC golimumab was 51%, and absorption was similar for the 3 in...Continue Reading

References

May 1, 1992·British Journal of Rheumatology·F M BrennanM Feldmann
Oct 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·K K Chan, M Gibaldi
Jan 1, 1994·European Journal of Clinical Pharmacology·J D JensenJ K Madsen
Feb 1, 1993·The American Review of Respiratory Disease·M Cembrzynska-NowakJ A Teodorczyk-Injeyan
Mar 9, 2000·Journal of Pharmaceutical Sciences·C J Porter, S A Charman
Aug 8, 2001·Advanced Drug Delivery Reviews·C J PorterS A Charman
Oct 10, 2006·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Risto S Cvetković, Lesley J Scott
May 17, 2008·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Greg L Plosker, Susan J Keam
Aug 15, 2008·Clinical Pharmacology and Therapeutics·C A HallerJ T Sullivan

❮ Previous
Next ❯

Citations

May 24, 2012·The AAPS Journal·Wolfgang F RichterMarilyn E Morris
Jul 9, 2010·Clinical Pharmacokinetics·Ron J KeizerJos H Beijnen
Jul 24, 2012·Therapeutic Delivery·Henryk MachMohammed Shameem
Jun 7, 2013·Annals of the Rheumatic Diseases·Bernard CombeUNKNOWN GO-MORE Investigators
Oct 1, 2013·Clinical Pharmacology in Drug Development·Wendy W CaiDavid C Subich
Jan 23, 2016·Immunotherapy·Valeria Rios Rodriguez, Denis Poddubnyy
Jan 29, 2016·Clinical Pharmacokinetics·Katherine L GillManoranjenni Chetty
Sep 17, 2015·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Gabriella BrömsHelle Kieler
Oct 25, 2012·Pharmacology & Therapeutics·Zhenhua XuHonghui Zhou
Mar 6, 2016·Drug Metabolism and Pharmacokinetics·Kenta HarayaTomoyuki Igawa
May 29, 2015·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Johannes Wohlrab
Oct 22, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Daniel SchweizerAchim Goepferich
Nov 8, 2016·Expert Opinion on Biological Therapy·Carlo PalazziIgnazio Olivieri
Apr 5, 2017·Pharmaceutical Research·Niels Vande Casteele, Reena Khanna
May 29, 2018·Expert Opinion on Drug Metabolism & Toxicology·Paul Malik, Andrea Edginton
Aug 26, 2017·Immunotherapy·Maria UrdanetaSonya Abraham
Feb 26, 2016·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·Won Moon
Sep 21, 2018·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Dennis R GouletAbhinav Nath
Aug 8, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Wolfgang F Richter, Björn Jacobsen
Nov 7, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Leonid Kagan, Donald E Mager
Aug 15, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Leonid Kagan
Feb 14, 2020·Paediatric Drugs·Zaid H TemrikarBernd Meibohm
Dec 11, 2019·Antibodies·Veena A Thomas, Joseph P Balthasar
May 17, 2014·Expert Review of Clinical Immunology·Marc D Cohen, Edward C Keystone
May 13, 2018·Clinical Pharmacokinetics·Sophie E BerendsRon A A Mathôt
Jan 20, 2011·Annals of Medicine·Zoe Ash, Paul Emery
Jul 26, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Beate BittnerJohannes Schmidt
Aug 17, 2019·British Journal of Clinical Pharmacology·Jill B Fiedler-KellyMicha Levi
Jun 6, 2020·Journal of Pharmacokinetics and Pharmacodynamics·Shihao Hu, David Z D'Argenio
Dec 29, 2020·Human Vaccines & Immunotherapeutics·Ana Teresa MeloJoão Eurico Fonseca
Aug 14, 2019·Journal of Pharmaceutical Sciences·Ninad VarkhedeM Laird Forrest

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.